Drug-Coated Balloons vs. Conventional Angioplasty Below the Knee

This meta-analysis is an update on the role of drug-coated balloons in the treatment of infrapopliteal arterial disease, a difficult pathology for all strategies.

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

The primary endpoint of this meta-analysis was treated lower limb salvage at 12 months. The secondary endpoints included survival at 12 months, amputation free survival, restenosis, and target lesion repeat revascularization rate.

This analysis included 10 studies and a total of 1593 patients, even though study quality was moderate to low, according to the standards.

The treated limb salvage rate was 94% with drug-coated balloons vs. 95.7% with conventional angioplasty, which is not a significant difference.


Read also: Crest-2 Registry: Carotid PCI Presents Low Rates of Death and Stroke.


The survival rate at one year was 89.8% vs. 92.9%, which is not a significant difference either.

An analysis of the 4 most uniform studies showed a 32.9% rate of restenosis with drug-coated balloons vs. a 62% rate with conventional angioplasty. This difference seems significant, but there is great dispersion in the confidence interval (odds ratio [OR]: 2.87; 95% confidence interval [CI]: 0.83 to 9.92).

The amputation free survival rate was 82.5% with drug-coated balloons vs. 88.7% with conventional angioplasty (OR: 0.79; 95% CI: 0.23 to 2.75).


Read also: How Much Should We Exercises to Reduce Mortality?


There were no significant differences in any of the studied endpoints.

Conclusion

Based on this systematic review and meta-analysis, there are no significant differences in terms of lower limb salvage, survival, restenosis, target lesion revascularization, or amputation free survival between angioplasty with drug-coated balloons and conventional angioplasty in infrapopliteal arterial disease.

Original Title: Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.

Reference: Jetty Ipema et al. Eur J Vasc Endovasc Surg, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...